Realtime | Geld | Brief | Zeit |
---|---|---|---|
4,220 | 4,420 | 29.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
WUXI XDC Aktie jetzt für 0€ handeln | |||||
Fr | WUXI XDC (02268): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
Fr | WUXI XDC (02268): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 27, 2025; (2) CHANGE OF DIRECTORS; AND (3) CHANGE IN COMPOSITION OF BOARD ... | - | HKEx | ||
28.05. | WUXI XDC (02268): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 27, 2025 | 1 | HKEx | ||
28.05. | WUXI XDC (02268): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
28.05. | WUXI XDC (02268): (1) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS (2) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND ... | 1 | HKEx | ||
28.05. | WUXI XDC (02268): CHANGE OF DATE OF ANNUAL GENERAL MEETING AND BOOK CLOSURE PERIOD | 1 | HKEx | ||
29.04. | WUXI XDC (02268): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
29.04. | WUXI XDC (02268): ANNUAL REPORT 2024 | - | HKEx | ||
14.04. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | - | HKEx | ||
25.03. | Contractors WuXi Bio, WuXi XDC eye continued growth after logging solid performances in 2024 | 5 | FiercePharma | ||
24.03. | WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024 | 150 | PR Newswire | Revenue increased by 90.8% YoY to RMB 4,052 million
Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that... ► Artikel lesen | |
24.03. | WUXI XDC (02268): INSIDE INFORMATION 2024 ANNUAL RESULTS PRESENTATION | 1 | HKEx | ||
24.03. | WUXI XDC (02268): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
12.03. | WuXi XDC and AbTis collaborate on antibody-drug conjugates | 1 | Pharmaceutical Technology | ||
03.03. | WUXI XDC (02268): NOTICE OF BOARD MEETING | - | HKEx | ||
15.01. | BRIEF: WuXi XDC's revenue, profit jump in 2024 | 1 | Bamboo Works | ||
15.01. | WUXI XDC (02268): POSITIVE PROFIT ALERT | 1 | HKEx | ||
14.01. | WuXi AppTec's Shares Jump After Selling 7.2% Stake in WuXi XDC for USD312 Million | 6 | Yicai Global | ||
20.08.24 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | 379 | PR Newswire | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VALNEVA | 2,420 | -0,49 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
EPIGENOMICS | 0,620 | -17,33 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/13.06.2025/13:00... ► Artikel lesen | |
AAP IMPLANTATE | 1,680 | +3,70 % | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
INFLARX | 0,696 | -0,43 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
MICROBOT MEDICAL | 2,082 | -1,98 % | Microbot Medical Inc.: Microbot Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY Endovascular Robotic System | Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass.... ► Artikel lesen | |
ALDEYRA | 3,246 | +0,65 % | Aldeyra-Aktie steigt nach FDA-Vereinbarung zum Krebsmedikament-Studiendesign | ||
IMMUNIC | 0,602 | +1,01 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
ONCO-INNOVATIONS | 1,380 | +0,73 % | CEO von Onco-Innovations hält am Mittwoch, den 2. Juli 2025 eine Sondertelefonkonferenz für Investoren ab | Vancouver, Kanada - 25. Juni 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben... ► Artikel lesen | |
CELLECTIS | 1,220 | -1,13 % | Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 | ||
ESPERION | 0,870 | +2,81 % | Cascale Talks ESPR at Innovation Forum Sustainable Apparel Event in Amsterdam | NORTHAMPTON, MA / ACCESS Newswire / May 14, 2025 / Elisabeth von Reitzenstein, senior director of policy and public affairs at Cascale, recently took to the stage at Innovation Forum's Sustainable Apparel... ► Artikel lesen | |
VERASTEM | 3,560 | 0,00 % | XFRA 2VSA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
SAGE THERAPEUTICS | 7,822 | +0,23 % | XFRA SG7: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
UNITY BIOTECHNOLOGY | 0,658 | -0,45 % | UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates | SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of... ► Artikel lesen | |
MESOBLAST | 0,930 | +0,54 % | Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil |